# Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

> **NCT02231008** · PHASE2,PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Smith-Magenis Syndrome
- Circadian

## Interventions

- **DRUG:** tasimelteon
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02231008
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2018-11-19
- **Final completion:** 2022-01
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2022-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02231008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02231008, "Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02231008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*